206 related articles for article (PubMed ID: 35655045)
1. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Pandy JGP; Franco PIG; Li RK
Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials.
Kao YS; Lo CH; Tu YK; Hung CH
Dermatol Ther; 2022 Oct; 35(10):e15774. PubMed ID: 36054263
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced hand foot syndrome: comparative efficacy and safety of pharmacological prophylaxis - systematic review and Bayesian network meta-analysis.
Ramasubbu MK; Maji S; Padhan M; Maiti R; Hota D; Majumdar SKD; Srinivasan A
BMJ Support Palliat Care; 2022 Dec; ():. PubMed ID: 36564149
[TBL] [Abstract][Full Text] [Related]
4. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
Lee YS; Jung YK; Kim JH; Cho SB; Kim DY; Kim MY; Kim HJ; Seo YS; Yoon KT; Hong YM; Lee JH; Lee HW; Yim HJ; Jang BK; Jang ES; Jang JY; Hwang SY
Eur J Cancer; 2020 Nov; 140():19-27. PubMed ID: 33039810
[TBL] [Abstract][Full Text] [Related]
5. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Santhosh A; Kumar A; Pramanik R; Gogia A; Prasad CP; Gupta I; Gupta N; Cheung WY; Pandey RM; Sharma A; Batra A
Trials; 2022 May; 23(1):420. PubMed ID: 35590388
[TBL] [Abstract][Full Text] [Related]
6. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
Huang XZ; Chen Y; Chen WJ; Zhang X; Wu CC; Wang ZN; Wu J
Int J Cancer; 2018 Jun; 142(12):2567-2577. PubMed ID: 29355976
[TBL] [Abstract][Full Text] [Related]
7. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis.
Lian S; Zhang X; Zhang Y; Zhao Q
Clin Exp Dermatol; 2021 Jun; 46(4):629-635. PubMed ID: 33190278
[TBL] [Abstract][Full Text] [Related]
8. Effect of Urea Cream on Hand-Foot Syndrome in Patients Receiving Chemotherapy: A Meta-analysis.
Lan TC; Tsou PH; Tam KW; Huang TW
Cancer Nurs; 2022 Sep-Oct 01; 45(5):378-386. PubMed ID: 34483284
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis.
Jo SJ; Shin H; Jo S; Kwon O; Myung SK
Clin Exp Dermatol; 2015 Apr; 40(3):260-70. PubMed ID: 25557587
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Toyama T; Yoshimura A; Hayashi T; Kobayashi N; Saito K; Tsuneizumi M; Sawaki M; Hattori M; Nakada T; Yokota I; Iwata H
Breast Cancer; 2018 Nov; 25(6):729-735. PubMed ID: 29948956
[TBL] [Abstract][Full Text] [Related]
13. Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study.
Lien RY; Tung HH; Wu SL; Hu SH; Lu LC; Lu SF
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1532. PubMed ID: 34910380
[TBL] [Abstract][Full Text] [Related]
14. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
15. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials.
Macedo LT; Lima JP; dos Santos LV; Sasse AD
Support Care Cancer; 2014 Jun; 22(6):1585-93. PubMed ID: 24463616
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
McLellan B; Ciardiello F; Lacouture ME; Segaert S; Van Cutsem E
Ann Oncol; 2015 Oct; 26(10):2017-26. PubMed ID: 26034039
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysis.
Zhou Y; Peng L; Li Y; Chen L
Biomed Rep; 2013 Nov; 1(6):873-878. PubMed ID: 24649045
[TBL] [Abstract][Full Text] [Related]
18. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
Watanabe K; Ishibe A; Watanabe J; Ota M; Fujii S; Ichikawa Y; Oba MS; Endo I
Indian J Gastroenterol; 2020 Apr; 39(2):204-210. PubMed ID: 32406009
[TBL] [Abstract][Full Text] [Related]
19. Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study.
Xiaozhe L; Meilan C; Beihui H; Junru L; Jingli G; Lifen K; Juan L
Integr Cancer Ther; 2022; 21():15347354221140402. PubMed ID: 36510385
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
Zhang RX; Wu XJ; Wan DS; Lu ZH; Kong LH; Pan ZZ; Chen G
Ann Oncol; 2012 May; 23(5):1348-1353. PubMed ID: 21940785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
